Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 18, 2025 16:30 ET Â | Source: Ultragenyx Pharmaceutical Inc. NOVATO, Calif.,…
Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital
CHICAGO, July 16, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a newly formed…
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
July 09, 2025 16:16 ET Â | Source: Rhythm Pharmaceuticals, Inc. BOSTON, July…
Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance
ROCKVILLE, Md. and SUZHOU, China, July 07, 2025 (GLOBE NEWSWIRE) -- Ascentage…
Abinopharm, Inc. and EGT Synbio Announce Successful Human Clinical Trials on Oral L-Ergothioneine (Dr.Ergo) for Skin Health
SHELTON, Conn., July 06, 2025 (GLOBE NEWSWIRE) -- Abinopharm, Inc., an innovative…
Verdiva Bio to Present New Data Highlighting Once-Weekly Potential of Its Investigational Oral Obesity Candidates at the ADA 85th Scientific Sessions
Phase 1 data evaluating VRB-101, Verdiva Bio’s cAMP-biased oral GLP-1RA, provides proof…
Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671
June 20, 2025 19:30 ET Â | Source: Structure Therapeutics Inc. SAN FRANCISCO,…
Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update
June 19, 2025 01:00 ET Â | Source: Addex Therapeutics Strong cash position…
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split
June 18, 2025 16:30 ET Â | Source: Cellectar Biosciences, Inc. FLORHAM PARK,…
Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025
June 18, 2025 01:00 ET Â | Source: Addex Therapeutics Geneva, Switzerland, June…